











































Glioblastoma	 multiforme	 is	 the	 most	 aggressive	 form	 of	 brain	 cancer	 due	 to	 high	 rates	 of	
reoccurrence.	 	 Although	 >95%	of	 a	 tumor	 can	 be	 removed	with	 surgery,	 the	 invasiveness	 of	
gliomas	 frequently	 leads	 to	 the	 formation	 of	 tumors	 at	 secondary	 sites.	 The	 invasiveness	 of	
gliomas	is	in	part	due	to	their	ability	to	secrete	proteolytic	enzymes,	including	members	of	the	






3	was	 significantly	 inhibited.	 Findings	 presented	 in	 this	 thesis	 indicate	 that	MMP-3	 activity	 is	
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BCA	 	 	 Bicinchoninic	Acid	
BSA	 	 	 Bovine	Serum	Albumin	
CM	 	 	 Conditioned	Media	
COSMIC	 	 Catalogue	of	Somatic	Mutations	in	Cancer	
DCM	 	 	 Dichloromethane	
DIC	 	 	 N,N'-Diisopropylcarbodiimide 
DMF	 	 	 Dimethylformamide	
DMSO	 	 	 Dimethyl	Sulfoxide	
Dnp	 	 	 N-2,4-dinitrophenyl	
DTT	 	 	 Dithiothreitol	
ECL	 	 	 Enhanced	Chemiluminescence	
ECM	 	 	 Extracellular	Matrix	
EtOH	 	 	 Ethanol	
FBS	 	 	 Fetal	Bovine	Serum	
Fmoc	 	 	 Fluorenylmethyloxycarbonyl 
GBM	 	 	 Glioblastoma	Multiforme	
IDH	 	 	 Isocitrate	dehydrogenase	
LC-MS/MS	 	 Liquid	Chromatography	Mass	Spectroscopy/Mass	Spectroscopy	
M	 	 	 Molarity	
Mca	 	 	 (7-methoxycoumarin-4-yl)acetyl	
MeOH	 	 	 Methanol	
mL	 	 	 Milliliter	
MMP	 	 	 Matrix	Metalloproteinase	
MMPI	 	 	 Matrix	Metalloproteinase	Inhibitor	
MOE	 	 	 Molecular	Operating	Environment	
MS	 	 	 Mass	Spectroscopy	
NMR	 	 	 Nuclear	Magnetic	Resonance	
	 xvi	
PBS	 	 	 Phosphate	Buffered	Saline	
PDB	 	 	 Protein	Data	Bank	
PI	 	 	 Propidium	Iodide	
TBST	 	 	 Tris-buffered	Saline	with	Tween	20	(Polysorbate	20)	
TCGA	 	 	 The	Cancer	Genome	Atlas	
THF	 	 	 Tetrahydrofuran	
TLC	 	 	 Thin	Layer	Chromatography		
TNBS	 	 	 2,	4,	6	–	trinitrobenzenesulfonic	acid	
Tp53	 	 	 Tumor	protein	53	
SDS	 	 	 Sodium	Dodecyl	Sulfate	
SILAC	 	 	 Stable	Isotope	Labeling	with	Amino	Acids	in	Cell	Culture	
UV	 	 	 Ultraviolet		
WHO	 	 	 World	Health	Organization	
WR	 	 	 Working	Reagent	




Cancer	 is	 a	 disease	 that	 has	 an	 impact	 on	 the	 lives	 of	 many	 humans.	 The	 World	 Health	
Organization	(WHO)	estimates	the	number	of	cancer	cases	rising	from	1.3	to	2.1	million	from	
2012	 to	 2030,	 in	 North	 and	 South	 America	 alone.1	 In	 addition,	 the	 number	 of	 Canadians	
diagnosed	with	cancer	within	their	lifetime	is	approximately	1	in	2.2	Cancer	is	the	uncontrolled	
division	of	cells	resulting	in	tumor	formation.	The	cause	of	this	uncontrolled	division	is	due	to	


























tumor	 suppressor	 pathway	 leading	 to	 uncontrolled	 proliferation;	 (2)	 activation	 of	
phosphatidylinositol-3-OH	kinase	(PI3K)	pathway	(PTEN	is	a	PI3K	pathway	antagonist	and	most	
















































































The	WHO	 uses	 a	 grading	 system	 to	 classify	 gliomas	 through	 characteristics	 to	 predict	 tumor	
malignancy.	Gliomas	are	classified	based	upon	the	cellular	morphology	of	the	tumor	cells,	which	































































Figure	 1.1.3:	 Tissue	 sections	 of	 different	 grade	 gliomas	 following	 the	 WHO	 classification	
system.	Classification	of	glioma	grade	based	upon	visual	characteristics.	A)	Glioblastoma	(Grade	








about	 10%	 of	 GBM	 cases,	 and	 is	 generally	 associated	 with	 younger	 patients12	 Another	
distinguishing	characteristic	between	primary	and	secondary	GBM	 is	 the	mutational	 status	of	
isocitrate	dehydrogenase	(IDH),		with	primary	GBM	maintaining	the	wild	type	version	of	the	IDH	
gene	and	secondary	GBM	having	the	IDH-mutant	gene.13		IDH	is	an	enzyme	of	the	citric	acid	cycle	
that	might	play	a	 role	 in	 cellular	defense	against	oxidative	 stress,	which	may	account	 for	 the	


















high	 grade	 glioma	 tumors	 to	 an	 appropriate	 subtype,	 these	 subtypes	 being:	 proneural,	
proliferative,	and	mesenchymal.16	Adding	on	to	the	work	done	by	Philips	et	al.	(2006),	a	further	
subtype	was	identified	by	using	200	GBM	and	two	normal	brain	samples	to	identify	210	signature	
genes	 per	 subtype.17	 The	 four	 subtypes	 redefined	 as	 proneural,	 neural,	 classical,	 and	
mesenchymal.		
	 The	proneural	subtype	is	generally	found	in	younger	patients	with	secondary	GBM,	and	























after	 95%	 of	 tumor	 is	 removed,	 the	 invasiveness	 of	 GBM	 leads	 to	 formation	 of	 tumors	 at	























































































condition	of	 the	microenvironment.28	Hypoxia	 is	 a	 state	 in	which	oxygen	 levels	 are	 low.	 Low	
oxygen	conditions,	or	hypoxic	conditions	are	common	in	areas	that	surround	necrotic	areas	of	
tumors.29	Often	tumor	hypoxia	is	associated	with	tumor	progression	and	the	aggressiveness	of	
the	 tumor.	 Hypoxia-inducible	 factors	 (HIF-1),	 regulate	 the	 cell	 response	 to	 hypoxia	 by	
transcriptional	 activation	 of	 downstream	 genes.30,31	 Activation	 of	 these	 downstream	 genes	
include	genes	involved	with	migration	and	invasion.31	HIF-1,	a	transcription	factor,	is	composed	
of	 HIF-1a	 (or	 analogs	 HIF-2a,	 HIF-3a)	 and	 HIF-1b.32,33	 HIF-1a,	 the	 most	 important	 subunit,	
dimerizes	with	HIF-1b,	which	is	the	constitutively	active	subunit,	to	prevent	degradation	of	HIF-
1,	 thus	 recruiting	 transcriptional	 co-activators	and	 initiating	gene	 transcription.20,34	GBM	cells	
overexpress	HIF-1a,	and	glioma	stem-like	cells	also	overexpress	HIF-2a.35		In	normoxic	conditions	
HIF-1a	has	a	half-life	of	approximately	5	minutes,	but	under	hypoxic	conditions	is	much	more	
stable	 due	 to	 several	 pathways.36	 The	 increased	 activation	 of	 HIF-1,	 leads	 to	 increased	
transcription	of	genes	associated	with	migration	and	invasion	including	ECM	remodeling	enzymes	
(MMPs,	cathepsins)	and	matricellular	proteins.	







Migration	 is	 directly	 connected	 to	 the	 microenvironment	 surrounding	 the	 cell.	 In	 order	 to	
migrate,	 the	 cell	 must	 modify	 its	 shape,	 which	 includes	 the	 cell	 becoming	 polarized	 and	
elongated.		
Overall,	there	are	five	steps	to	migration:	1)	The	first	step	is	the	protrusion	of	the	leading	
edge	 of	 the	 cell.	 (Figure	 1.2.1	 1)	 This	 protrusion	 is	 created	 by	 actin	 filaments	within	 the	 cell	
connecting	to	adaptor	proteins,	resulting	in	the	cell	membrane	being	pushed	outward,	elongating	
the	cell.37	In	addition	to	the	leading	edge	of	the	migrating	cell,	necrotic	areas	of	the	tumor	express	
cells	 with	 pseudopalisades.30	 These	 populations	 of	 pseudopalisades	 characteristically	 express	
more	stem	cell-like	markers	and	migrate	away	from	the	hypoxic	regions.30,38	The	pseudopalisades	
are	believed	to	be	connected	to	the	aggressiveness	and	malignancy	of	GBM.38	Pseudopalisades	
overexpress	HIF-1a	 than	compared	to	adjacent	 tumor	cells.38,39	The	HIF-1a	 is	 localized	to	the	
leading	invasive	edge	of	the	tumor	and	the	genes	regulated	by	HIF-1a	control	the	amount	of	ECM	
degradation,	 and	 therefore	 the	 invasiveness.29	 2)	 The	 second	 step	 is	 ECM	 interaction	 and	
formation	of	focal	contacts	(Figure	1.2.1	2).	The	leading	edge	of	the	cell	then	comes	in	contact	
with	 the	 adjacent	 ECM	 and	 binds	 to	 the	 ECM	 via	 integrins,	 creating	 focal	 contacts.40	 3)	 The	
recruitment	of	proteases.	The	involvement	of	integrins	signals	for	surface	proteases	to	become	





































migration.	 In	amoeboid	migration,	 there	 is	no	proteolytic	ECM	remodeling,	 cells	 rely	on	path	
finding	 and	 squeezing/flowing	 through	 spaces	 in	 the	 ECM.	 Cells	 that	 fit	 into	 mesenchymal	
migration	follow	the	migration	mechanism	outlined	above	(Figure	1.2.1).	The	types	of	cells	that	
follow	mesenchymal	migration	are	primarily	from	connective-tissue	tumors,	such	as	GBM.	These	
















































































terms	 of	 migration.43	 Collagen	 can	 also	 act	 as	 a	 storage	 systems	 for	 growth	 factors,	
proteoglycans,	 etc.	 which	 can	 be	 released,	 through	 collagen	 remodeling,	 based	 upon	 the	





































































just	 their	 ability	 to	 degrade	 the	 ECM.54	 MMPs	 have	 the	 ability	 to	 degrade	 cell-adhesion	
molecules,	 modulate	 both	 cell-cell	 interactions	 and	 cell-ECM	 interactions	 leading	 to	 the	
progression	of	cancer.26	MMPs	have	been	associated	with	multiple	cancer	processes	including:	



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































P3 P2 P1 Zn2+ P1’ P2’ P3’
P A N/E L/I/V I/V G/A P/D
A	– alanine L	– leucine	
D	– aspartic	acid N	– asparagine	
E	– glutamic	acid P	– proline	
G	– glycine V	– valine	
I	– isoleucine	
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Appendix	2	
	
Appendix	2:	Monoisotopic	(M)	mass,	theroretical	M+H	mass,	and	the	experimental	M+H	
determined	by	LC-MS/MS	for	the	compounds	Leu-Trp,	AP-1,	and	AP-2.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Compound Monoisotopic	(M)	
Mass
Theoretical M+H Experimental	
M+H
330.2056 331.2056 331.2177
442.1442 443.1442 443.1669
466.1708 467.1708 467.1723
AP-1
AP-2
Leu-Trp
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[M+H]+:	443.1442
AP-1
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Appendix	3:	Mass	spectrometry	results	for	Leu-Trp,	AP-1,	and	AP-2.	Experimental	M+H	values	
located	under	each	spectra	correspond	to	the	peaks	determined	by	mass	spectrometry	for	each	
compound.	
	
	
	
	
	
	
	
	
	
	
	
	
	
